🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Why can RNA only be linear or circular? It can be branched! We made multi-tailed mRNA, and we had fun! Here is our story led by brilliant graduate student Hongyu Chen: rdcu.be/dB7ck and his cartoon illustration👇MIT Chemistry Broad Institute

What is the incidence of T-cell malignancies after CAR-T? Magdi Elsallab, MD, PhD, of Mass General Cancer Center, and Moataz Ellithi, of University of Nebraska Medical Center, stopped by BCT to discuss their FAERS database analysis on T-cell malignancies after CAR-T. 📺 Watch here: buff.ly/4aYtiqu

Carl June and I reviewed the current evidence on the potential risk of T-cell lymphoma after #CART immunotherapy. Now online Blood Cancer Discovery !!! Penn Medicine Penn Medicine - Abramson Cancer Center rb.gy/im1r7i

🚀 Join Our Team at Baylor College of Medicine! 🧬 We’re looking for passionate technician to join our lab at Center for Cell and Gene Therapy. Help us develop innovative and accessible cell therapies for cancer and autoimmunity using genome editing. Pls RT 🙏 jobs.bcm.edu/job/Research-T…

More momentum on the #POC manufacturing front. Enter, regional blood banks. Galapagos Blood Centers of America glpg.com/press-releases…

Happy to see our work on the cover of @BloodJournal! If you haven’t read it yet, check out our study analyzing FDA adverse event reports for second primary malignancies post-CAR T cells: authors.elsevier.com/a/1j5wZ1UYwnBkJ

Great overview of the cellular immunotherapy landscape.

The FDA has approved the first telomerase inhibitor, imetelstat, to treat myelodysplastic syndromes following an epic journey for the drug, which has been tested in more than 20 trials over the past 20 years in various cancers. Find out more here bit.ly/4ekijKL

Preprint alert 🚨 Up to 90% CAR knock-in rates in primary human T cells - without drug enhancers? 🧐 Single-stranded HDR templates with truncated Cas12a binding sequences improve knock-in efficiencies in primary human T cells biorxiv.org/content/10.110… 🧵👇

check out Eva Gottwein's new preprint carefully measuring the toxicity of some CRISPRa activation systems. This is an issue today for functional genomics research and potentially for future therapeutics that use synthetic transcriptional activators biorxiv.org/content/10.110…

Harvard-MIT Center for Regulatory Science Director Florence Bourgeois, former CRS fellow Magdi Elsallab, MD, PhD, and former visiting student Sandra Gillner, publish JAMA Internal Medicine study comparing evidence submitted to the FDA and EMA for cell and gene therapies. Find the full study here: jamanetwork.com/journals/jamai…

The Hospital Clínic de Barcelona & Medical College of Wisconsin are rethinking how #CAR-T therapies are manufactured. Read our feature on the topic sohoinsider.com/news/spains-mo… Nirav Shah Magdi Elsallab, MD, PhD Leticia Alserawan

Discrepancies in clinical trial evidence reported to the FDA and EMA for cell and gene therapies highlight the need for harmonization in regulatory submissions. ja.ma/421j4Eo